Cargando…

BLyS/APRIL dual inhibition for IgG4-RD: a prospective single-arm clinical trial of telitacicept

Detalles Bibliográficos
Autores principales:	Cai, Shaozhe, Hu, Ziwei, Chen, Yu, Chen, Yuxue, Ming, Bingxia, Gao, Rongfen, Li, Zhen, Ye, Cong, Zhong, Jixin, Dong, Lingli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313947/ https://www.ncbi.nlm.nih.gov/pubmed/36657954 http://dx.doi.org/10.1136/ard-2022-223529

Ejemplares similares

Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes)
por: Stohl, William
Publicado: (2010)

Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model
por: Bath, Natalie M., et al.
Publicado: (2019)

Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys
por: Jagessar, S. Anwar, et al.
Publicado: (2012)

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels
por: Collins, Christopher E, et al.
Publicado: (2006)

Erratum to: Antibodies Against Human BLyS and APRIL Attenuate EAE Development in Marmoset Monkeys
por: Jagessar, S. Anwar, et al.
Publicado: (2012)

The current status of targeting BAFF/BLyS for autoimmune diseases
por: Ramanujam, Meera, et al.
Publicado: (2004)

Autoantibody production significantly decreased with APRIL/BLyS blockade in murine chronic rejection kidney transplant model
por: Bath, Natalie M., et al.
Publicado: (2019)

Proteomic characteristics of saliva in patients with different subgroups of IgG4-RD
por: Lin, Sheng-Yan, et al.
Publicado: (2022)

Potential roles of non-lymphocytic cells in the pathogenesis of IgG4-related disease
por: Cai, Shaozhe, et al.
Publicado: (2022)

G-CSF–stimulated Neutrophils Are a Prominent Source of Functional BLyS
por: Scapini, Patrizia, et al.
Publicado: (2003)

Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin
por: Parameswaran, Reshmi, et al.
Publicado: (2012)

BlyS is up-regulated by hypoxia and promotes migration of human breast cancer cells
por: Zhu, Jing, et al.
Publicado: (2012)

Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
por: Gordon, Caroline, et al.
Publicado: (2016)

Clinical characteristics of IgG4-RD patients infected with COVID-19 in Hubei, China
por: Chen, Yu, et al.
Publicado: (2020)

APRIL/BLyS deficient rats prevent donor specific antibody (DSA) production and cell proliferation in rodent kidney transplant model
por: Bath, Natalie M., et al.
Publicado: (2022)

SLE - Systemic lupus erythematosus: a BLySful, yet BAFFling, disorder
por: Stohl, William
Publicado: (2003)

Human BLyS Facilitates Engraftment of Human PBL Derived B Cells in Immunodeficient Mice
por: Schmidt, Madelyn R., et al.
Publicado: (2008)

Belimumab: Anti-BLyS Monoclonal Antibody; Benlysta™; BmAb; LymphoStat-B
Publicado: (2012)

Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab
por: Roth, D A, et al.
Publicado: (2015)

Multiple Processes May Involve in the IgG4-RD Pathogenesis: An Integrative Study via Proteomic and Transcriptomic Analysis
por: Cai, Shaozhe, et al.
Publicado: (2020)

Roles for BLyS family members in meeting the distinct homeostatic demands of innate and adaptive B cells
por: Sindhava, Vishal J., et al.
Publicado: (2013)

B Lymphocyte Stimulator (BLyS) Is Expressed in Human Adipocytes In Vivo and Is Related to Obesity but Not to Insulin Resistance
por: Müller, Nike, et al.
Publicado: (2014)

A pathogenic IFNα, BLyS and IL-17 axis in Systemic Lupus Erythematosus patients
por: López, Patricia, et al.
Publicado: (2016)

Fusion Toxin BLyS-Gelonin Inhibits Growth of Malignant Human B Cell Lines In Vitro and In Vivo
por: Luster, Troy A., et al.
Publicado: (2012)

Role of telitacicept in the treatment of IgA nephropathy
por: Wu, Lijun, et al.
Publicado: (2023)

Serum Soluble TACI, a BLyS Receptor, Is a Powerful Prognostic Marker of Outcome in Chronic Lymphocytic Leukemia
por: Kyrtsonis, Marie-Christine, et al.
Publicado: (2014)

Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation
por: Goenka, Radhika, et al.
Publicado: (2014)

Efficacy and safety of Telitacicept in patients with IgA nephropathy
por: Liang, Dongrui, et al.
Publicado: (2023)

Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab
por: Regola, Francesca, et al.
Publicado: (2019)

Telitacicept for autoimmune nephropathy
por: Cai, Jingjing, et al.
Publicado: (2023)

Enhanced immunogenicity of pneumococcal surface adhesin A (PsaA) in mice via fusion to recombinant human B lymphocyte stimulator (BLyS)
por: Gor, Dennis O, et al.
Publicado: (2011)

High Expression Levels of BLyS/BAFF by Blood Dendritic Cells and Granulocytes Are Associated with B-cell dysregulation in SIV-Infected Rhesus Macaques
por: Poudrier, Johanne, et al.
Publicado: (2015)

Blood B Lymphocyte Stimulator (BLyS)/BAFF levels may reflect natural immunity to HIV in highly exposed uninfected Beninese Commercial Sex Workers
por: Sabourin-Poirier, Catherine, et al.
Publicado: (2016)

Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria
por: Lv, Jicheng, et al.
Publicado: (2022)

Increased B-cell activating factor (BAFF)/B-lymphocyte stimulator (BLyS) in primary antiphospholipid syndrome is associated with higher adjusted global antiphospholipid syndrome scores
por: van den Hoogen, Lucas L, et al.
Publicado: (2018)

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus
por: Furie, Richard, et al.
Publicado: (2008)

Natural Immunity to HIV is associated with Low BLyS/BAFF levels and low frequencies of innate marginal zone like CD1c(+) B-cells in the genital tract
por: Fourcade, Lyvia, et al.
Publicado: (2019)

The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis
por: Wilkinson, Christel, et al.
Publicado: (2020)

Case report: Successful treatment of refractory membranous nephropathy with telitacicept
por: Zhang, Lei, et al.
Publicado: (2023)

IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from human marginal zone B cells as well as from circulating peripheral blood B cells from autoimmune patients
por: Ettinger, Rachel, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_rbk44m9nn2ol2d70puf8vrjt3a